Boehringer Ingelheim and Eli Lilly Announce NMPA Approval of Empagliflozin for Chronic Kidney Disease in Adults in China

On November 24, Boehringer Ingelheim andEli Lilly(LLY.US) Jointly announced that the new indication for its diabetes alliance's SGLT2 inhibitor Jardiance® (empagliflozin) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adult chronic kidney disease (CKD).

It is reported that this is another new indication for Jardiance® approved in China, following adult type 2 diabetes, heart failure with reduced ejection fraction in adults, heart failure with preserved ejection fraction in adults, and combination insulin therapy for type 2 diabetes. Together with the existing indications for type 2 diabetes and heart failure, Jardiance® helps manage risks caused by cardio-renal-metabolic diseases. Since its launch, it has benefited more than 1 billion patients worldwide.

Editor: Guo Mingyu